SALUDA MEDICAL INC (SLD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

SLD - SALUDA MEDICAL INC

FNArena Sector : NONE
Year End: June
GICS Industry Group : Classification Pending
Debt/EBITDA: -1.74
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$1.39

18 Dec
2025

-0.100

OPEN

$1.49

-6.71%

HIGH

$1.49

169,477

LOW

$1.39

TARGET
$2.80 101.4% upside
FNARENA'S MARKET CONSENSUS FORECASTS
SLD: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 137.5 - 66.8 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: N/A

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 N/A

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 20242025
EPS Basic xxx-137.5
DPS All xxx0.0
Sales/Revenue xxx108.6 M
Book Value Per Share xxx-447.2
Net Operating Cash Flow xxx-182.6 M
Net Profit Margin xxx-212.21 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20242025
Return on Capital Employed xxx-
Return on Invested Capital xxx-446.03 %
Return on Assets xxx-119.14 %
Return on Equity xxx-
Return on Total Capital xxx-119.75 %
Free Cash Flow ex dividends xxx-184.5 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20242025
Short-Term Debt xxx200 M
Long Term Debt xxx113 M
Total Debt xxx313 M
Goodwill - Gross xxx-
Cash & Equivalents - Generic xxx83 M
Price To Book Value xxx-

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20242025
Capex xxx2.0 M
Capex % of Sales xxx1.81 %
Cost of Goods Sold xxx58 M
Selling, General & Admin. Exp & Other xxx233 M
Research & Development xxx55 M
Investments - Total xxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

18/12/2025

1

Initiation of coverage with Speculative Buy

$2.80

101.44%

Bell Potter has initiated coverage of Saluda Medical with a Speculative Buy rating and target price of $2.80.

The company is a commercial-stage medtech selling spinal cord stimulation (SCS) therapy, with its closed-loop Evoke system differentiated by deeper, more durable pain relief and strong clinical/clinician support.

It addresses a key weakness of conventional SCS, lack of efficacy. The broker reckons the key upside is accelerating US share in a US$2.2bn market dominated by four incumbents. US revenue has already exceeded US$50m in less than 3 years but is still only 2% share.

The recent IPO proceeds are aimed at scaling the US commercial footprint, deepening penetration in existing accounts and launching paddle leads in FY27. Revenue is forecast to grow to US$290m by FY29 from around US$82m in FY26.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -66.84 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -52.85 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

SLD STOCK CHART

FNArena News on SLD

1
Next Week At A Glance – 22-24 Dec 2025

Dec 19 2025 - Weekly Reports